Add time:07/27/2019 Source:sciencedirect.com
BackgroundCOPD patients have increased risk of pneumonia when treated with fluticasone propionate (FP), whereas this is generally not the case with budesonide (BUD) treatment. We hypothesized that BUD and FP differentially affect the expression of immune defense genes.
We also recommend Trading Suppliers and Manufacturers of LEAD IV PROPIONATE (cas 19183-30-3). Pls Click Website Link as below: cas 19183-30-3 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View